PreMoLGA: A First Trimester Prediction Model for Large for Gestational Age Infants: a Preliminary Study

Sponsor
University of Modena and Reggio Emilia (Other)
Overall Status
Terminated
CT.gov ID
NCT04838431
Collaborator
(none)
503
1
19
26.5

Study Details

Study Description

Brief Summary

Large for gestational age infants (LGA) have increased risks of adverse short-term perinatal outcomes. This study aims to develop a multivariable prediction model for the risk of giving birth to a LGA baby, by using biochemical, biophysical, anamnestic, and clinical maternal characteristics available at first trimester.

This prospective study includes all singleton pregnancies attending the first trimester aneuploidy screening at the Obstetric Unit of the University Hospital of Modena, in Northern Italy.

Condition or Disease Intervention/Treatment Phase
  • Other: Blood sample and ultrasound at first trimester

Detailed Description

For each subject, blood sample is collected in fasting conditions, then centrifuged, and the serum stored at minus 80° C, for subsequent biochemical analyses. PAPP-A, PlGF and Inibin A is measured with the automated DELFIA EXPRESS system (Thermo Fisher Scientific, Perkin Elmer ®). Insulin, high density lipoproteins (HDL) and triglycerides are measured through routine laboratory methods.

The mean arterial pressure (MAP) is measured with validated automated devices (Dinamap, BLTV6XX). After the women are seated and allowed to rest for 3-5 min, normal (22 to 32 cm) adult cuffs are fitted to their both arms. This is repeated two times with 1 min break in between. The MAP is calculated with the formula MAP DBP + 1/3(SBP - DBP) 21, where DBP represents diastolic blood pressure and SBP, systolic blood pressure. We calculate the final MAP as the average of all four measurements. Uterine artery Doppler studies including pulsatility index are measured through trans-abdominal ultrasound (Voluson E8 or Voluson E10) examinations. As indicated in Fetal Medicine Foundation (FMF), when carrying out Doppler studies, color flow mapping is used to identify each uterine artery along the side of the cervix and uterus at the level of the cervical internal os. Pulsed wave Doppler imaging is used with the sampling gate set at 2 mm to cover the whole vessel, and care is taken to ensure that the angle of insonation is less than 30°. When three to five similar consecutive waveforms are obtained, PI is measured. The uterine artery mPI is calculated by adding the right and left pulsatility index together, divided by two. All ultrasound and Doppler studies are carried out by a physician who had received the appropriate certificate of competence in the 11-13+6 week scans and Doppler study from the FMF.

Data on pregnancy outcome are collected from the hospital maternity records or directly from women if delivered elsewhere.

Medical records are reviewed by research associates to obtain anonymized data on mothers (i.e maternal demographics, BMI, age…) and their newborns (birthweight, gender, Apgar score, admission to the neonatal intensive care unit (NICU) and length of stay, neonatal morbidities, and mortality), and are organized in a password protected database.

Study Design

Study Type:
Observational
Actual Enrollment :
503 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Development of a Prediction Model for Large for Gestational Age Infants at First Trimester: a Preliminary Study
Actual Study Start Date :
Jun 1, 2018
Actual Primary Completion Date :
Jun 30, 2019
Actual Study Completion Date :
Dec 31, 2019

Outcome Measures

Primary Outcome Measures

  1. LGA [From 37-42 weeks]

    Risk for delivering a LGA infant, by combining the birtweight, the infant gender and the gestational age at birth

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Singleton pregnancies attending the first trimester Down syndrome screening at the University Hospital of Modena, in the North of Italy (tertiary Hospital).
Exclusion Criteria:
  • Twin pregnancies

  • Pregnancies with major fetal abnormalities

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital of Modena Modena Italy 41124

Sponsors and Collaborators

  • University of Modena and Reggio Emilia

Investigators

  • Principal Investigator: Fabio R Facchinetti, MD, University of Modena and Reggio Emilia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prof. Fabio Facchinetti, Director of the Obstetrics and Gynecolocy department, University of Modena and Reggio Emilia
ClinicalTrials.gov Identifier:
NCT04838431
Other Study ID Numbers:
  • AOU: 0001395/20
First Posted:
Apr 9, 2021
Last Update Posted:
May 24, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Prof. Fabio Facchinetti, Director of the Obstetrics and Gynecolocy department, University of Modena and Reggio Emilia
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 24, 2022